Abstract
The aim of this study was to determine the dose-limiting toxicity (DLT) and establish the recommended dose for mitomycin C added every 3 weeks to the standard combination dose of capecitabine. Cohorts of at least three patients with pretreated gastrointestinal carcinoma received capecitabine 1000 mg m(-2) orally twice daily on days 1-14 plus i.v. bolus mitomycin C on day 1 at doses of 4, 6, 8 or 10 mg m(-2) (corresponding to dose levels I-IV). Cycles were repeated every 3 weeks. Two treatment cycles were considered for the evaluation of DLTs. Of the 53 patients enrolled, the majority had colorectal (n=27) or gastric (n=14) cancers. Patients had received a median of two lines of prior chemotherapy (34% with >/=3 lines and 87% with prior 5-FU-based therapy). At the recommended dose level (IV, n=30), grade 3 adverse events during cycles 1 and 2 were: anaemia (10%); leukopenia (3%); thrombocytopenia (3%); stomatitis/mucositis (3%); hand-foot syndrome (3%). Two patients experienced DLTs (mucositis, n=1; neutropenic fever, n=1), but there were no grade 4 events. The median dose intensity for capecitabine and mitomycin C was 100% during cycles 1 and 2 and only four patients required postponement of therapy. Of the 43 patients evaluabl...Continue Reading
References
Mar 1, 1989·European Journal of Cancer & Clinical Oncology·O RusselloA Sobrero
Dec 24, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P RossJ Oates
Apr 1, 2000·Lancet·J Y DouillardP Rougier
Feb 7, 2001·Cancer Chemotherapy and Pharmacology·J SchüllerB Reigner
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A de GramontA Bonetti
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Feb 14, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C Twelves, UNKNOWN Xeloda Colorectal Cancer Group
Mar 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Markus M BornerArnaud D Roth
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P RossA Norman
Jun 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M VenturiniR Rosso
Jun 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J CassidyUNKNOWN Capecitabine Colorectal Cancer Study Group
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joyce O'ShaughnessyRobert Leonard
Jul 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nick MaiseyMark Hill
Dec 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W ScheithauerG V Kornek
Sep 5, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M TewesU Vanhoefer
Dec 4, 2003·British Journal of Cancer·J T HartmannC Bokemeyer
Mar 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G V KornekW Scheithauer
May 13, 2004·British Journal of Cancer·R-D HofheinzA Hochhaus
Citations
Dec 15, 2005·Journal of Surgical Oncology·Yutaka OgataKazuo Shirouzu
May 4, 2010·Expert Opinion on Investigational Drugs·Anastasios DimouMuhammad Wasif Saif
Mar 18, 2005·Onkologie·Jochen RudiRalf-Dieter Hofheinz
Aug 11, 2005·British Journal of Cancer·G ChongN Tebbutt
Nov 15, 2007·British Journal of Cancer·T ErnstR-D Hofheinz
Feb 22, 2014·Journal of Cancer Research and Clinical Oncology·Manuel Barreto MirandaKirsten Merx
May 18, 2016·Anti-cancer Drugs·Fausto PetrelliSandro Barni
Jun 10, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemJ Zalcberg